Abraxane FDA Approval History
FDA Approved: Yes (First approved January 7, 2005)
Brand name: Abraxane
Generic name: paclitaxel protein-bound
Dosage form: for Injectable Suspension
Company: American Pharmaceutical Partners, Inc. / American Bioscience, Inc.
Treatment for: Breast Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer
Abraxane (paclitaxel protein-bound) is an albumin-bound form of the antineoplastic agent paclitaxel indicated for the treatment of breast cancer, non-small cell lung cancer, and pancreatic cancer.
Development Timeline for Abraxane
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.